US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

Finnish biopharmaceutical company Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to use the proceeds for funding further clinical development, R&D of new hypoallergens and business development.   Desentum develops novel immunotherapeutic hypoallergens, so called allergy vaccines. The hypoallergens are biotechnologically produced, modified allergen proteins aimed for

Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Desentum Oy, a clinical-stage biopharmaceutical company developing novel immuno­therapies for treating allergies, today announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a favourable immunological response.“We are very happy to have completed the clinical study despite the challenges posed by the Covid-19 pandemic. The preclinical models available for testing allergen immunotherapy products are

Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments

Finnish biopharmaceutical company Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends to use for funding clinical trials, developing new hypoallergens and advancing business goals.Desentum develops novel type of immunotherapeutic hypoallergens, so called allergy vaccines. The hypoallergens are biotechnologically produced, modified allergen proteins aimed for improving the

Finnish Biopharmaceutical Company Desentum Wins a 1.9 M€ EU Grant for Testing Birch Pollen Allergy Vaccine

ESPOO, Finland, 29 October 2018 – Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, has been awarded a 1.9 M€ grant from the European Innovation Council pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine for birch pollen allergy. Allergen immunotherapy usually takes several years but Desentum aims at reducing the time to 3–6 months without compromising safety and efficacy.

There are no items matching the current filter
There are no more items matching the current filter
Back to top